Strauss RW, et al. - This research entailed an elucidation of the yearly progression rate of atrophic lesions in the retrospective Progression of Stargardt Disease study. The findings illustrated that fundus autofluorescence could present as a monitoring tool for interventional clinical trials that focus on slowing the disease progression, in Stargardt disease with definitely decreased autofluorescence (DDAF) lesions. Rates of progression were primarily based on the initial lesion size.